ArtesunĀ®

Guilin, a Fosun Pharma company

Product category
  • Artesunate for injection

Therapeutic indication
  • Treatment of severe malaria caused by the parasite P. falciparum, to be followed by a full course of ACT

Dosing
  • At least 3 injections within 1 day (during critical phase)

  • 30mg, 60mg, 120mg

Efficacy
  • 92% survival vs 88% survival with quinine in African children

  • Coma scores, convulsions, and hypoglycaemia significantly less frequent with artesunate compared to quinine 

  • Pharmacovigilance conducted in collaboration with African Collaboration Center proved that injectable artesunate has a favorable safety profile

Key features
  • WHO-prequalified injectable artesunate

Challenges
  • Concern from disease-endemic countries regarding single-source supply

  • Potential for delayed haemolytic anaemia

Status
  • WHO prequalification 2010

  • Approved in 34 countries (see map); >127 million vials shipped since prequalification, with >800k estimated lives saved since WHO PQ

Next milestone
  • Simplified injectable artesunate two vial to be developed for WHO PQ review before 2020
MMV Project Director
  • Pierre Hugo